Want to see INSP full AI Analyst Report?
INSP Stock Chart & Stats
$57.59
-$1.46(-0.68%)
At close: 4:00 PM EST
$57.59
-$1.46(-0.68%)
Day’s Range― - ―
52-Week Range$38.91 - $147.03
Previous CloseN/A
Volume95.34K
Average Volume (3M)1.01M
Market Cap
$1.53B
Enterprise Value$1.23K
Total Cash (Recent Filing)$283.83M
Total Debt (Recent Filing)$29.55M
Price to Earnings (P/E)11.8
Beta0.61
Next Earnings
Aug 03, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.53
Shares Outstanding28,813,152
10 Day Avg. Volume932,662
30 Day Avg. Volume1,007,095
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.47
Price to Sales (P/S)2.97
P/FCF Ratio34.52
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$52.27Price Target Upside-9.23% Downside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)0.9
Revenue Forecast (FY)$843.31M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~85% gross margins are a durable competitive advantage for an implantable device: they provide strong unit economics, fund clinical and commercial investments, and cushion reimbursement pressure, enabling scalable profitability as volumes normalize over months.
Strong Balance Sheet & CashA cash cushion (~$400M) and extremely low leverage give the company runway to weather reimbursement disruption, sustain field support and R&D, and invest in coding/reimbursement remediation without forcing dilutive financing in the 2–6 month horizon.
Clinical Momentum & Installed BaseExtensive clinical evidence and a large installed base (>135k patients) create durable adoption barriers: positive trial outcomes and published studies support physician confidence and payer conversations, underpinning long-term procedure demand and reimbursement resolution efforts.
Bears Say
Coding & Reimbursement UncertaintyOngoing CPT/code ambiguity forces manual reviews and inconsistent payer handling, materially slowing case submissions and approvals. Until a stable coding solution (targeted 2028) is adopted, procedure volumes and revenue realization face structurally elevated friction and timing risk.
WISER Prior-Auth HeadwindThe AI-reviewed WISER prior-authorization pilot has created tangible, multi-quarter volume loss by delaying Medicare approvals. If the pilot or similar programs persist or scale, approval lead times and case throughput could remain depressed, compressing near-term procedure growth.
Profitability & Cash-Flow VariabilityWhile profitability improved recently, margins and free-cash-flow have shown year-to-year swings and tax items (SBC-related) create episodic GAAP volatility. This uneven earnings convertibility reduces near-term predictability for reinvestment and longer-term margin sustainability planning.
Inspire Medical Systems News
INSP FAQ
What was Inspire Medical’s price range in the past 12 months?
Inspire Medical lowest stock price was $38.91 and its highest was $147.03 in the past 12 months.
What is Inspire Medical’s market cap?
Inspire Medical’s market cap is $1.53B.
When is Inspire Medical’s upcoming earnings report date?
Inspire Medical’s upcoming earnings report date is Aug 03, 2026 which is in 12 days.
How were Inspire Medical’s earnings last quarter?
Inspire Medical released its earnings results on May 04, 2026. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of -$0.275 by $0.375.
Is Inspire Medical overvalued?
According to Wall Street analysts Inspire Medical’s price is currently Overvalued.
Does Inspire Medical pay dividends?
Inspire Medical does not currently pay dividends.
What is Inspire Medical’s EPS estimate?
Inspire Medical’s EPS estimate is -0.23.
How many shares outstanding does Inspire Medical have?
Inspire Medical has 28,813,152 shares outstanding.
What happened to Inspire Medical’s price movement after its last earnings report?
Inspire Medical reported an EPS of $0.1 in its last earnings report, beating expectations of -$0.275. Following the earnings report the stock price went down -12.017%.
Which hedge fund is a major shareholder of Inspire Medical?
Currently, no hedge funds are holding shares in INSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inspire Medical Systems Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$52.27 (-9.23% Downside)
$52.27 (-9.23% Downside)
Blogger Sentiment
Bullish
INSP Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $144.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
24.71%
Trailing 12-Months
Company Description
Inspire Medical
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
INSP Revenue Breakdown
97.02% U.S.
2.98% Other
INSP Stock 12 Month Forecast
Average Price Target
$52.27
▼(-9.23% Downside)
Technical Analysis
Integer Holdings
―
LivaNova
―
Irhythm Technologies
―
TransMedics Group
―
PROCEPT BioRobotics
―
Ownership Overview
1.69% Insiders
28.73% Mutual Funds
3.19% Other Institutional Investors
38.98% Public Companies and
Individual Investors